aTYR PHARMA INC (ATYR): Cash & Equivalents
$10.74M
As of 2025-12-31
$16.16M
As of 2026-06-30
+2.5%
3-year compound annual growth
-8.7%
5-year compound annual growth
-14.8%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.74M | -2.8% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $11.05M | -51.0% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $22.54M | +125.9% | 2026-03-05, Balance as of period end |
| 2022-12-31 | $9.98M | +327.3% | 2025-03-13, Balance as of period end |
| 2021-12-31 | $2.34M | -86.2% | 2024-03-14, Balance as of period end |
| 2020-12-31 | $16.95M | +84.1% | 2023-03-14, Balance as of period end |
| 2019-12-31 | $9.21M | -59.9% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $22.96M | +8.9% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $21.09M | -45.1% | 2019-03-26, Balance as of period end |
| 2016-12-31 | $38.39M | -27.6% | 2019-03-26, Balance as of period end |
| 2015-12-31 | $53.02M | +281.5% | 2018-03-20, Balance as of period end |
| 2014-12-31 | $13.90M | -61.9% | 2017-03-16, Balance as of period end |
| 2013-12-31 | $36.46M | n/a | 2016-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $10.74M | -2.8% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $5.02M | -55.6% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $2.98M | +75.5% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $24.75M | +18.3% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $7.11M | -17.9% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
| Pluri Inc. (PLUR) | 2026-06-30 | $3.53M | -40.1% |
Compare ATYR, VIVS, AIM, CRDF side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗